The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $197.44

Today's change-1.85 -0.93%
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $197.44

Today's change-1.85 -0.93%
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc crosses below 20-day moving average

Alexion Pharmaceuticals Inc closed lower Friday, dropping (U.S.)$1.85 or 0.93% to (U.S.)$197.44 and crossing below its 20-day moving average. Shares have lost 1.77% over the last five days, but have gained 6.71% over the last year to date. This security has outperformed the S&P 500 by 15.21% during the last year.

Key company metrics

  • Open(U.S.) $200.00
  • Previous close(U.S.) $199.29
  • High(U.S.) $200.00
  • Low(U.S.) $196.32
  • Bid / Ask-- / --
  • YTD % change+6.71%
  • Volume1,697,910
  • Average volume (10-day)1,533,021
  • Average volume (1-month)1,635,267
  • Average volume (3-month)2,267,361
  • 52-week range(U.S.) $150.06 to (U.S.) $208.88
  • Beta0.58
  • Trailing P/E67.47×
  • P/E 1 year forward40.99×
  • Forward PEG2.43×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.93
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+24.78%

Based on its net profit margin of 24.78%, Alexion Pharmaceuticals Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.60%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue600599555512
Total other revenue--------
Total revenue600599555512
Gross profit531550503473
Total cost of revenue69495240
Total operating expense497396318294
Selling / general / administrative187184158159
Research & development2161259789
Depreciation / amortization5433
Interest expense (income), net operating--------
Unusual expense (income)193382
Other operating expenses, total--------
Operating income104204237219
Interest income (expense), net non-operating-1-1----
Gain (loss) on sale of assets--------
Other--------
Income before tax107205236219
Income after tax91153178166
Income tax, total16525852
Net income91153178166
Total adjustments to net income--------
Net income before extra. items91153178166
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items91153178166
Inc. avail. to common incl. extra. items91153178166
Diluted net income91153178166
Dilution adjustment----00
Diluted weighted average shares202202201202
Diluted EPS excluding extraordinary itemsvalue per share0.450.760.880.83
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.530.880.910.83